Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers. 1987

M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller

This was a randomized, crossover study of the bioavailability and pharmacokinetics of metoclopramide given by intranasal (IN), oral (PO), and intramuscular (IM) routes. The formulations tested were 5 and 10 mg of IN gel, 10 mg PO, and 5 mg IM. The findings showed that metoclopramide follows similar absorption and elimination characteristics when given via these three extravascular routes. There were no statistically significant differences in the area under the drug concentration versus time curve (AUC) or peak metoclopramide plasma concentration (Cmax) data following PO, IM, or 10-mg IN administration. However, the 5-mg IN doses achieved an AUC that was 39.5% the AUC of the 10-mg IN dose. These data show consistent and relatively predictable metoclopramide plasma concentrations following IN administration. Further, 10-mg doses of IN and PO metoclopramide appear to be bioequivalent.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008433 Mathematics The deductive study of shape, quantity, and dependence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Mathematic
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
August 2009, Alimentary pharmacology & therapeutics,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
September 2006, Biopharmaceutics & drug disposition,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
September 1990, International journal of clinical pharmacology, therapy, and toxicology,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
April 1995, Journal of clinical pharmacy and therapeutics,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
November 2015, Clinical therapeutics,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
January 2023, Clinical pharmacology in drug development,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
August 1992, Journal of clinical pharmacology,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
January 2007, Journal of clinical pharmacology,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
July 2018, European journal of clinical pharmacology,
M L Citron, and J R Reynolds, and J Kalra, and B G Kay, and K A Nathan, and N D Jaffe, and F R Miller
April 2005, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!